1. The Kv11.3 (hERG3) potassium channel plays a critical role in the regulation of autophagy in melanoma cells.
2. Pharmacologic stimulation of the Kv11.3 channel with a small molecule activator, NS1643, induces autophagy via activation of an AMPK-dependent signaling pathway and inhibits cell proliferation by activating a cellular senescence program.
3. Inhibition of autophagy via siRNA targeting AMPK or treatment with hydroxychloroquine activates apoptosis in NS1643-treated cells, suggesting that use of a combinatorial pharmacologic approach of Kv11.3 activator with inhibitors of autophagy may represent a novel therapeutic approach against melanoma.
The article is generally reliable and trustworthy as it provides evidence for its claims through experiments and data analysis, such as Western blot analyses, flow cytometry analyses, AnnexinV apoptosis detection, confocal microscopy imaging, and quantification using Image J software. The authors also provide clear explanations for their findings and conclusions throughout the article.
However, there are some potential biases to consider when evaluating the trustworthiness and reliability of this article. For example, the authors do not explore any counterarguments to their findings or discuss any possible risks associated with their proposed therapeutic approach against melanoma. Additionally, they do not present both sides equally; instead they focus solely on the potential benefits of their proposed approach without considering any potential drawbacks or limitations that could arise from its implementation in clinical practice. Furthermore, there is no mention of any conflicts of interest among the authors which could potentially influence their results or conclusions in some way.